Merck & Co. to Initiate P-II Study of MK-5890 for Non-Small Cell Lung Cancer
Shots:
- The P-II study will evaluate MK-5890 + Keytruda (pembrolizumab) in patients with sq. and non-sq. NSCLC prior treated with anti-PD-L1 therapy. The study is the part of pembrolizumab umbrella master protocol (MK-3475-U01)
- In 2014- Merck signed WW license agreement with Aduro to develop & commercialize MK-5890- under which Aduro received $10M as development milestones on the initiation of P-II study of MK-5890
- Aduro’s MK-5890 is an anti-CD27 agonist- demonstrated a T-cell enhancement in combination with an immune checkpoint inhibitor and showed complete tumor eradication in its preclinical studies
Click here to read full press release/ article
Ref: Aduro | Image: Merck
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com